에서 이용할 수 있어요!
자세히 알아보기
Mentari Therapeutics, Inc. Common Stock
MTRI
MTRI
소개: Mentari Therapeutics Inc is a biotechnology company engaged in the development of therapies for the prevention of migraine. Its product pipeline includes MT-001, an anti-PACAP monoclonal antibody, and MT-002, a bispecific antibody targeting both CGRP and PACAP pathways. The company's research and development activities focus on therapeutic candidates targeting PACAP and CGRP-related mechanisms for migraine prevention.
뉴스
긍정적
중립
부정적
투자 심리
3개월
긍정적
0%
중립
100%
부정적
0%
가격 차트는 Lightweight Charts™ 라이브러리로 구현했어요